1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Increased myocardial stiffness more than impaired relaxation function limits cardiac performance during exercise in heart failure with preserved ejection fraction: a virtual patient study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Aims

          The relative impact of left ventricular (LV) diastolic dysfunction (LVDD) and impaired left atrial (LA) function on cardiovascular haemodynamics in heart failure with preserved ejection fraction (HFpEF) is largely unknown. We performed virtual patient simulations to elucidate the relative effects of these factors on haemodynamics at rest and during exercise.

          Methods and results

          The CircAdapt cardiovascular system model was used to simulate cardiac haemodynamics in wide ranges of impaired LV relaxation function, increased LV passive stiffness, and impaired LA function. Simulations showed that LV ejection fraction (LVEF) was preserved (>50%), despite these changes in LV and LA function. Impairment of LV relaxation function decreased E/ A ratio and mildly increased LV filling pressure at rest. Increased LV passive stiffness resulted in increased E/ A ratio, LA dilation and markedly elevated LV filling pressure. Impairment of LA function increased E/ A ratio and LV filling pressure, explaining inconsistent grading of LVDD using echocardiographic indices. Exercise simulations showed that increased LV passive stiffness exerts a stronger exercise-limiting effect than impaired LV relaxation function does, especially with impaired LA function.

          Conclusion

          The CircAdapt model enabled realistic simulation of virtual HFpEF patients, covering a wide spectrum of LVDD and related limitations of cardiac exercise performance, all with preserved resting LVEF. Simulations suggest that increased LV passive stiffness, more than impaired relaxation function, reduces exercise tolerance, especially when LA function is impaired. In future studies, the CircAdapt model can serve as a valuable platform for patient-specific simulations to identify the disease substrate(s) underlying the individual HFpEF patient’s cardiovascular phenotype.

          Graphical Abstract

          Related collections

          Most cited references36

          • Record: found
          • Abstract: not found
          • Article: not found

          2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The perindopril in elderly people with chronic heart failure (PEP-CHF) study.

              Many patients who receive a diagnosis of heart failure have neither a low left ventricular (LV) ejection fraction nor valve disease. Few substantial randomized controlled trials have been conducted in this population, none has focussed on patients with evidence of diastolic dysfunction and none has shown clear benefit on symptoms, morbidity, or mortality. This was a randomized double-blind trial, comparing placebo with perindopril, 4 mg/day in patients aged > or =70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease. The primary endpoint was a composite of all-cause mortality and unplanned heart failure related hospitalization with a minimum follow-up of 1 year. A total of 850 patients were randomized. Their mean age was 76 (SD 5) years and 55% were women. Median follow-up was 2.1 (IQR 1.5-2.8) years. Enrollment and event rates were lower than anticipated, reducing the power of the study to show a difference in the primary endpoint to 35%. Many patients withdrew from perindopril (28%) and placebo (26%) after 1 year and started taking open-label ACE-inhibitors. Overall, 107 patients assigned to placebo and 100 assigned to perindopril reached the primary endpoint (HR 0.919: 95% CI 0.700-1.208; P = 0.545). By 1 year, reductions in the primary outcome (HR 0.692: 95% CI 0.474-1.010; P = 0.055) and hospitalization for heart failure (HR 0.628: 95% CI 0.408-0.966; P = 0.033) were observed and functional class (P < 0.030) and 6-min corridor walk distance (P = 0.011) had improved in those assigned to perindopril. Uncertainty remains about the effects of perindopril on long-term morbidity and mortality in this clinical setting since this study had insufficient power for its primary endpoint. However, improved symptoms and exercise capacity and fewer hospitalizations for heart failure in the first year were observed on perindopril, during which most patients were on assigned therapy, suggesting that it may be of benefit in this patient population.
                Bookmark

                Author and article information

                Journal
                Eur Heart J Digit Health
                Eur Heart J Digit Health
                ehjdh
                European Heart Journal. Digital Health
                Oxford University Press
                2634-3916
                November 2020
                23 November 2020
                23 November 2020
                : 1
                : 1
                : 40-50
                Affiliations
                [1 ] Department of Biomedical Engineering, CARIM School for Cardiovascular Diseases, Maastricht University , PO Box 616, 6200 MD, Maastricht, the Netherlands
                [2 ] Department of Cardiology, Maastricht University Medical Center , PO Box 616, 6200 MD, Maastricht, the Netherlands
                [3 ] Department of Physiology, CARIM School for Cardiovascular Diseases, Maastricht University , PO Box 616, 6200 MD, Maastricht, the Netherlands
                [4 ] Bakken Research Center, Medtronic , Maastricht, the Netherlands
                Author notes
                Corresponding author. Tel: +31 43 388 1659, Email: t.vanloon@ 123456maastrichtuniversity.nl
                Author information
                http://orcid.org/0000-0001-6897-9700
                http://orcid.org/0000-0001-8129-7384
                Article
                ztaa009
                10.1093/ehjdh/ztaa009
                9707905
                36713963
                8da6b3d4-a310-4204-b0b6-fa7b0764dc09
                © The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

                History
                : 08 October 2020
                : 08 October 2020
                : 08 October 2020
                Page count
                Pages: 11
                Funding
                Funded by: Dutch Heart Foundation;
                Award ID: 2015T082
                Funded by: ERA-CVD JTC2018;
                Award ID: 2018T094
                Funded by: Netherlands Organization for Scientific Research;
                Funded by: NWO-ZonMw;
                Award ID: 016.176.340
                Categories
                Original Articles

                diastolic dysfunction,myocardial relaxation,passive stiffness,exercise intolerance,computer modelling,virtual patient simulation

                Comments

                Comment on this article